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Abstract 
Background: Visit-to-visit office blood pressure variation (BPV) has prognostic implications 
independent from mean BP across several populations in the cardiovascular field. The 
association of BPV with outcomes in patients with myocardial infarction (MI) with systolic 
dysfunction and/or heart failure (HF) is yet to be determined. 
Methods: Two independent cohorts were assessed: the EPHESUS and the OPTIMAAL trials 
with a total of >12,000 patients. The primary outcome was all-cause death. BPV was calculated 
as a coefficient of variation, i.e. the ratio of the standard-deviation to the mean BP along the 
post-baseline follow-up. Cox regression models were used to determine the associations 
between BPV and events.  
Results: Compared to the middle and lower BPV tertiles, patients in the upper BPV tertile were 
older, more often female, hypertensive, diabetic, with peripheral artery disease, and had more 
frequent use of loop diuretics and ACEi/ARBs. They also had lower LVEF, hemoglobin, and 
eGFR (all p<0.001). BPV was independently associated with worse prognosis in a U-shaped 
manner. In the EPHESUS trial, both low and high BPV were associated with higher rates of 
death (and also CV death and the composite of CV death/CV hospitalization): adjusted HR 
(95%CI) for the outcome of death=1.99 (1.68-2.36) for high BPV and =1.60 (1.35-1.90) for low 
BPV. Similar results were observed in the OPTIMAAL trial population. 
Conclusion: In two independent cohorts of MI patients with systolic dysfunction and/or HF, 
BPV was associated with worse prognosis in a U-shaped manner independently of the mean BP. 
 
Key-words: visit to visit blood pressure variability; outcomes; myocardial infarction; heart 
failure. 
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Introduction 
Visit-to-visit office blood pressure variability (BPV) has prognostic implications 
independent of mean blood pressure (BP) across several populations in the cardiovascular field1-
6. High BPV may be related to one or more of autonomic dysfunction, arteriosclerosis, increased 
sympathetic tone, arterial stiffness, some blood pressure-lowering agents and treatment non-
adherence7-13.  
Most studies have reported an association between  high office systolic BPV and worse 
prognosis in the general population and in patients with hypertension3. However, in heart failure 
patients with reduced ejection fraction (HF-REF) the results have been inconsistent4, 13. For 
example, in subanalysis derived from the Effects of high-dose versus low-dose losartan on 
clinical outcomes in patients with heart failure trial (HEAAL), a high BPV was found to be 
associated with poorer cardiovascular (CV) outcomes13. On the other hand, in the Ivabradine 
and outcomes in chronic heart failure trial (SHIFT) was the low BPV that was associated with 
worse outcomes4.  
To the best of our knowledge, the association between office BPV and outcomes in 
patients with myocardial infarction (MI) complicated by left ventricular systolic dysfunction 
and/or HF setting have not been reported before and were therefore examined in the present 
study.    
 
Methods 
Study population 
The derivation cohort was patients enrolled in the Eplerenone Post–Acute Myocardial 
Infarction Heart Failure Efficacy and Survival Study (EPHESUS)14, 15. The Optimal Trial in 
Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) was used for 
validation16, 17. Full details of the design and results of each trial are published14, 17. In short, both 
trials enrolled patients with left ventricular systolic dysfunction, HF or both between 12 h and 
14 days after acute MI.  
The studies were all conducted in accordance with the Declaration of Helsinki and 
approved by site ethics committees. All participants gave written informed consent to 
participate in the trials. 
Outcomes 
The primary outcome in both trials was all-cause death (with a coprimary endpoint of 
CV death or CV hospitalization in EPHESUS). We analyzed the association between BPV and 
the primary outcome of death in both EPHESUS and OPTIMAAL, exploring the association of 
BPV with CV death and CV hospitalization in the EPHESUS trial.    
Visit-to-visit blood pressure variation 
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Blood pressure was measured in each trial at each visit after 5 min of rest in the seated 
position by a trained observer using an automated oscillometric monitor. Three measures were 
performed systematically and the mean of the 3 measures was calculated and inserted in the 
dataset. BPV was previously shown to be reproducible and applicable in clinical practice18. The 
average of several measurements over time has been shown to provide more precise information 
on the risk for cardiovascular events in a population of patients with stable chronic 
cardiovascular disease19. Mean BP was calculated using measurements at each follow-up visit. 
BPV was calculated as a coefficient of variation, that is, the ratio of the standard deviation (SD) 
to the mean (CV=SD/mean*100%). Measurements from all follow-up visits were included. 
Altogether, a mean±SD of 7.7±2.7 visits (range, 2–14) were available in EPHESUS and 8.8±3.0 
(range, 2-12) in OPTIMAAL.   
Statistical methods 
Continuous variables were expressed as mean±SD and categorical variables as 
frequencies and proportions. For comparison of means and proportions, one-way ANOVA test 
and chi-square test were used, respectively. 
Factors associated with BPV (tertiles) were first identified using univariate followed by 
multivariable stepwise backward conditional multinomial logistic regression using the 
intermediate BPV category as reference. The covariates inserted in the models were identified 
among patient characteristics listed in Table 1 with a p-value <0.1. Linearity was assessed by 
plotting the β-estimates vs. mean by quintiles of the studied independent variable. Variables were 
then categorized in order to obtain log-linearity. Multinomial logistic regression data are 
presented as odds ratios (OR) and respective 95% confidence intervals (95%CI).  
Cox proportional hazard regression models were used to model long-term survival as a 
function of the formulas both in univariable and multivariable analysis. Proportional hazards 
assumptions for dependent variables were visually assessed by plotting the log(-log(S(t))) 
function as a function of survival time (t), where S(t) represents the survival function. In the 
multivariable models, the adjustment covariates were chosen from demographic (age and 
gender), clinical/pharmacological (mean systolic blood pressure, heart rate, history of diabetes 
mellitus, hypertension, peripheral vascular disease, chronic obstructive pulmonary disease, left 
ventricular ejection fraction, diuretics, ACEi/ARB, and beta-blockers use, and also eplerenone 
allocation), and laboratory variables (hemoglobin, sodium, and estimated glomerular filtration 
rate calculated by the CKD-EPI equation20) that were previously found to be clinically 
relevant21. Additional adjustment in smoking status, alcohol consumption, mean heart rate and 
heart rate variability was also performed. These variables had a small proportion of missing 
values (<10%) and no multiple imputation was performed. We assessed interactions with the 
Log of time, age, sex, mean systolic blood pressure, heart rate, pulse pressure and eplerenone 
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allocation and none were significant (all p >0.10). The correlation between BPV, blood pressure 
SD, mean blood pressure and pulse pressure are presented in the results section. Whenever the 
correlation between two variables was >0.5 only one of them was inserted in the multivariable 
models due to colinearity issues. 
The linearity assumption of the relationship between BPV and the log-hazard of 
outcome was assessed using restricted cubic splines with 3 knots equally spaced at the 10th, 
50th and 90th percentiles according to the Harrell´s rule22. The Wald test associated with the 
nonlinear component was statistically significant, and a nonlinear relationship was assumed 
regarding all the studied outcomes (p value for linearity <0.001). Supplemental Figure 1 & 2.  
A p-value <0.05 was considered as statistically significant. 
All analysis was performed with the R® software. R Core Team (2013). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL: http://www.R-project.org/. 
 
Results 
Baseline characteristics 
 The BPV tertiles were:  ≤7.7 % (n=2180), 7.8-10.9 % (n=2163) and >10.9 % (n=2164). 
The absolute number of BP evaluations was similar across each tertile (n≈8). The mean systolic 
BP at baseline in each tertile was: 119.8 ± 14.5, 119.4 ± 16.0 and 118.2 ± 18.5 mmHg, 
respectively (p=0.004). For diastolic BP the respective values were 73.4 ± 10.0, 72.4 ± 10.4 and 
70.6 ± 11.3 mmHg (<0.0001). Compared to those in the middle and lower BPV tertiles, patients 
in the upper BPV tertile in EPHESUS were older and more often female, but less often 
Caucasian.  They more commonly had hypertension, diabetes, peripheral artery disease, and 
chronic obstructive pulmonary disease; they were more often treated with loop diuretics and 
ACEi/ARBs. Patients in the upper BPV tertile also had a lower mean left ventricular ejection 
fraction, hemoglobin, and estimated glomerular filtration rate (all p <0.001). Similar results 
were observed in the OPTIMAAL trial. Table 1 & Supplemental Table 1. 
The integer (%) of BPV tertiles was also similar between the EPHESUS and 
OPTIMAAL trials (low ≤8% in EPHESUS vs. ≤9% in OPTIMAAL and high ≥11% for both). 
Table 1 & Supplemental Table 1. 
Logistic regression analysis to determine the factors associated with BP variability  
  In the EPHESUS multivariable logistic regression analysis, lower BPV was 
independently and positively associated with Caucasian race (OR, 95%CI=1.37, 1.10-1.69) and 
pulse pressure <40 mmHg (OR, 95%CI=1.37, 1.17-1.61), and negatively associated with 
diabetes (OR, 95%CI=0.87, 0.76-0.99), peripheral vascular disease (OR, 95%CI=0.72, 0.60-
0.88), SBP <120 mmHg (OR, 95%CI=0.84, 0.73-0.96) and use of ACEi/ARBs (OR, 
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95%CI=0.77, 0.65-0.91). On the other hand, higher BPV was independently and positively 
associated with age >70 years (OR, 95%CI=1.21, 1.05-1.39), SBP <120 mmHg (OR, 
95%CI=1.24, 1.09-1.42), eGFR <60 ml/min/1.73m2 (OR, 95%CI=1.19, 1.04-1.37) and use of 
ACEi/ARBs (OR, 95%CI=1.35, 1.12-1.63), and negatively associated with male gender (OR, 
95%CI=0.80, 0.70-0.92) and pulse pressure <40 mmHg (OR, 95%CI=0.74, 0.62-0.87). The 
middle BPV tertile (i.e. intermediate BP variability) was used as the reference tertile. Table 2. 
In the OPTIMAAL trial data hypertension and estimated glomerular filtration rate <60 
ml/min/1.73m2 were also associated with high BPV. Supplemental Table 2. 
Prognostic associations 
 BPV was independently associated with worse prognosis in a U-shaped manner. In 
EPHESUS, both low and high BPV were associated with higher event rates of death, CV death 
and the composite of CV death or CV hospitalization: adjusted HR (95% CI) for the outcome of 
death =1.99 (1.68-2.36) for low BPV and 1.60 (1.35-1.90) for high BPV. Similar results were 
observed for the other studied outcomes (CV death and CV death or CV hospitalization). 
Overlapping replication was found in the OPTIMAAL trial. Table 3, Figure 1 & 
Supplemental Table 3. A sensitivity analysis including patients with a minimum of 3 visits 
plus further adjustment on smoking status and alcohol consumption was also performed, 
providing overlapping results to those above described. Supplemental Table 4. Additional 
adjustment on the mean heart rate and its variability did not change the associations and no 
statistical interaction was present. Supplemental Table 5.  
Data consistency  
For simplification of the manuscript the data shown herein refer to systolic BPV, 
referred to as BPV throughout the text. The results for diastolic BPV were similar to those of 
systolic BPV. Supplemental Figure 3. Systolic and diastolic BPV were moderately correlated 
(Pearson correlation=0.51, p<0.0001). 
The correlation between the SD and the coefficient of variation of both systolic and 
diastolic BPV was strong (Pearson correlation=0.97 for both) and provided overlapping results. 
Systolic BPV was weakly correlated with mean SBP and mean pulse pressure (Pearson 
correlation <0.20). The prognostic associations of BPV were independent from the mean BP 
and pulse pressure. 
 
Discussion 
 Among MI patients with systolic dysfunction and/or HF, those with low BPV differed 
substantially from those with high BPV with respect to their baseline characteristics. Despite 
these baseline differences, BPV was independently associated with worse prognosis in a U-
shaped manner i.e. both low and high BPV were independently associated with higher event 
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rates compared to the rates observed in patients with intermediate BPV. These findings were 
replicated in two independent MI cohorts and provide novel information about BPV in this 
population. 
 The mean BPV (≈9%) observed in these MI patients with systolic dysfunction and/or 
HF was similar to that described for other high CV-risk populations such as heart failure with 
HF-REF, hypertension, stroke, coronary artery disease, and receiving hemodialysis5, 13, 23, 24. 
However, in these other populations a high BPV was consistently associated with worse 
prognosis. The only exception was in SHIFT, where in patients with HF-REF a low BPV was 
associated with higher event rates (compared to patients with intermediate and high BPV 
tertiles) with a significant statistical interaction between BPV and mean systolic BP whereby 
those at highest risk were in the subgroup with the lowest third of mean SBP and lowest third of 
BPV4. However, the mechanisms underpinning this association of low BPV with adverse 
outcomes in SHIFT are unknown4. One potential explanation might relate to the association 
between low BPV and low pulse pressure in EPHESUS (although not in OPTIMAAL). In 
patients with acute MI and/or HF-REF, low pulse pressure may reflect low stroke volume, and 
in these populations a lower pulse pressure is associated with worse outcomes25-27. 
Consequently, in EPHESUS, low BPV, might also reflect a lower stroke volume. However, this 
remains uncertain as the U-shaped association of V BPV was independent of the pulse pressure 
and no statistical interaction was observed.  
The association of high BPV with higher morbidity and mortality reported in several 
patient-populations has been attributed to modifications on the factors influencing regional 
circulation and blood pressure10-13. In EPHESUS, high BPV was positively associated with older 
age, renal dysfunction, low systolic blood pressure, and higher use of ACEi/ARBs. In 
hypertensive populations, the use of ACEi/ARBs (and beta-blockers) was also found to be 
associated with increased BPV compared to calcium-channel blockers and non-loop diuretics9. 
Nonetheless, the clinical relevance of these findings is yet to be determined and warrants 
prospective assessment9.  
 To the best of our knowledge, this is the first report of a U-shaped BPV association with 
outcomes in MI populations with systolic dysfunction and/or HF. The similar number of 
measures across the BPV spectrum plus the independence and replication of these results in two 
independent cohorts make these findings robust24. 
 Currently there are multiple evidence-based life-saving therapies for patients with the 
characteristics of those described herein28, 29. Specifically targeting BPV in this population 
seems unlikely because one would have to avoid both low and high BPV simultaneously. 
However, further studies are warranted to understand the underlying mechanisms that link low 
BPV to increased morbidity and mortality rates.      
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Limitations 
 Several limitations in our study should be noticed. First, this is a post-hoc analysis of 
two randomized controlled trials, therefore the limitations inherent to observational studies are 
present in our report and no causality can be established. Second, the differences reported 
between BPV groups are likely due to between-group differences in patients` characteristics, 
rather than to on-treatment differences.  Third, adherence to treatment along the trial is not 
reported in the dataset, however, in randomized trials patients’ high motivation and close 
follow-up make overall adherence uncharacteristically high as compared to population-based 
studies. Fourth, these trials did not target hypertension, hence there was no predefined BP 
intervention at baseline which may have influenced BPV. Moreover, we also did not observe a 
treatment allocation interaction. Fifth, the EPHESUS and OPTIMAAL trials had different 
inclusion criteria. While EPHESUS required a LVEF≤40%, OPTIMAAL included patients with 
a LVEF≤35% or a left-ventricular end-diastolic dimension ≥65 mm and/or a new Q-wave 
anterior-wall acute myocardial infarction, or any reinfarction with previous pathological Q-
waves in the anterior wall. These differences between the studies may account for the observed 
discrepancies in the factors associated with BPV. However, they reinforce the external validity 
of our results in complicated MI populations. Lastly, the mechanisms underlying BPV are not 
completely understood (especially for the association of low BPV with worse prognosis) and 
further studies are required. Specifically, high sympathetic activity could be associated with low 
BPV and portend adverse prognosis. However, we do not have sympathetic activity indexes 
available in the datasets. 
 
Conclusion 
In MI patients with systolic dysfunction and/or HF, BPV is associated with worse 
prognosis in a U-shaped fashion independently of the mean BP. Further studies are warranted to 
understand the underlying mechanisms related to BPV. 
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Table 1. EPHESUS: Population characteristics by blood pressure variability tertiles 
Characteristics 
 
N. 
 
Global pop. 
 
T1: ≤7.7 %  
(N=2180) 
T2: 7.8-10.9 % 
(N=2163) 
T3: >10.9 % 
(N=2164) 
p-value 
 
Age, years 6632 64.0 ± 11.5 62.5 ± 11.8 63.7 ± 11.1 65.5 ± 11.4 <0.0001 
Male, n (%) 6632 4714 (71.1 %) 1617 (74.2 %) 1575 (72.8 %) 1434 (66.3 %) <0.0001 
Caucasian, n (%) 6632 5984 (90.2 %) 2009 (92.2 %) 1946 (90.0 %) 1923 (88.9 %) 0.0009 
Hypertension, n (%) 6632 4007 (60.4 %) 1239 (56.8 %) 1317 (60.9 %) 1375 (63.5 %) <0.0001 
Diabetes, n (%) 6632 2142 (32.3 %) 626 (28.7 %) 717 (33.1 %) 757 (35.0 %) <0.0001 
AFib, n (%) 6632 874 (13.2 %) 259 (11.9 %) 301 (13.9 %) 284 (13.1 %) 0.13 
PVD, n (%) 6632 823 (12.4 %) 216 (9.9 %) 292 (13.5 %) 298 (13.8 %) <0.0001 
COPD, n (%) 6632 625 (9.4 %) 187 (8.6 %) 189 (8.7 %) 233 (10.8 %) 0.022 
Previous MI, n (%) 6632 1802 (27.2 %) 593 (27.2 %) 562 (26.0 %) 611 (28.2 %) 0.25 
HF history, n (%) 6632 975 (14.7 %) 328 (15.0 %) 291 (13.5 %) 337 (15.6 %) 0.12 
LVEF, % 6617 33.1 ± 6.1 33.5 ± 6.0 33.1 ± 6.0 32.8 ± 6.1 0.002 
Hemoglobin, g/dL 6556 13.3 ± 1.7 13.4 ± 1.7 13.3 ± 1.7 13.2 ± 1.7 <0.0001 
Sodium, mmol/L 6587 139.4 ± 4.4 139.7 ± 4.8 139.4 ± 4.1 139.3 ± 4.2 0.014 
Potassium, mmol/L 6586 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.5 0.047 
eGFR, ml/min/1.73m2 6587 68.4 ± 20.9 69.8 ± 20.4 69.3 ± 21.0 66.2 ± 21.0 <0.0001 
BMI, Kg/m2 6611 27.4 ± 4.5 27.4 ± 4.5 27.4 ± 4.4 27.4 ± 4.7 0.81 
SBP, mmHg 6630 119.1 ± 16.5 119.8 ± 14.5 119.4 ± 16.0 118.2 ± 18.5 0.004 
DBP, mmHg 6630 72.1 ± 10.7 73.4 ± 10.0 72.4 ± 10.4 70.6 ± 11.3 <0.0001 
Pulse pressure, mmHg 6630 48.9 ± 10.5 46.9 ± 9.3 48.8 ± 9.9 51.4 ± 11.3 <0.0001 
Heart Rate, bpm 6628 74.7 ± 11.7 75.0 ± 11.3 74.6 ± 11.6 74.2 ± 12.1 0.078 
Killip III/IV, n (%) 6507 1302 (19.8 %) 409 (18.9 %) 420 (19.6 %) 438 (20.4 %) 0.48 
Loop diuretics, n (%) 6507 3661 (55.2 %) 1136 (52.1 %) 1152 (53.3 %) 1288 (59.5 %) <0.0001 
Thiazides, n (%) 6507 540 (8.1 %) 182 (8.3 %) 173 (8.0 %) 179 (8.3 %) 0.91 
ACEi/ARBs, n (%) 6507 5751 (86.7 %) 1817 (83.3 %) 1883 (87.1 %) 1946 (89.9 %) <0.0001 
Beta-blockers, n (%) 6507 4961 (74.8 %) 1629 (74.7 %) 1614 (74.6 %) 1637 (75.6 %) 0.69 
SBP variability coef., % 6507 9.8 ± 4.3 5.7 ± 1.7 9.3 ± 0.9 14.3 ± 3.8 <0.0001 
N. SBP measures, n (%) 6632 7.7 ± 2.7 7.4 ± 2.7 8.3 ± 2.4 7.7 ± 2.6 <0.0001 
Eplerenone allocation, n (%) 6632 3319 (50.0 %) 1117 (51.2 %) 1100 (50.9 %) 1043 (48.2 %) 0.093 
Death, n (%) 6632 1032 (15.6 %) 360 (16.5 %) 220 (10.2 %) 366 (16.9 %) <0.0001 
CV death, n (%) 6632 890 (13.4 %) 321 (14.7 %) 186 (8.6 %) 299 (13.8 %) <0.0001 
CV death/CV hosp., n (%) 6632 1878 (28.3 %) 596 (27.3 %) 519 (24.0 %) 675 (31.2 %) <0.0001 
Legend: AFib, atrial fibrillation; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; 
MI, myocardial infarction; HF, heart failure; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular 
filtration rate; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACEi/ARBs, 
angiotensin converting enzyme inhibitors/angiotensin receptor blockers; CV, cardiovascular; T, tertiles. 
T1, low SBP variability; T2, intermediate SBP variability; T3, high SBP variability.  
 
 
 
 
 
 
 
Table 2. EPHESUS: Multinomial logistic regression to assess the factors associated with low 
and high blood pressure variability using intermediate variability as reference category 
 
Variables Low (≤7.7 %) vs.  
Intermediate (7.8-10.9 %) 
High (>10.9 %) vs.  
Intermediate (7.8-10.9 %) 
 OR (95%CI) p-value OR (95%CI) p-value 
Age >70 years - NS 1.205 (1.047-1.387) 0.010 
Male gender (yes) - NS 0.803 (0.700-0.920) 0.002 
Caucasian race (yes) 1.366 (1.103-1.692) 0.004 - NS 
Diabetes (yes) 0.865 (0.757-0.988) 0.033 - NS 
PVD (yes) 0.724 (0.598-0.878) 0.001 - NS 
SBP <120 mmHg 0.837 (0.732-0.956) 0.009 1.243 (1.087-1.420) 0.001 
Pulse pressure <40 mmHg 1.373 (1.173-1.607) <0.001 0.737 (0.622-0.874) <0.001 
eGFR <60 ml/min/1.73m2 - NS 1.191 (1.040-1.367) 0.012 
ACEi/ARBs (yes) 0.769 (0.648-0.912) 0.003 1.350 (1.116-1.633) 0.002 
Legend: PVD, peripheral vascular disease; SBP, systolic blood pressure at baseline; eGFR, estimated glomerular 
filtration rate at baseline; ACEi/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor blockers use at 
baseline. 
Low SBP variability: ≤7.7 %; Intermediate SBP variability: 7.8-10.9 %; High SBP variability: >10.9 %.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. EPHESUS: Prognostic associations of blood pressure variability  
Outcome SBP variability Univariable: HR (95CI%) p-value Adjusted: HR (95CI%)* p-value 
Death 
Low (≤7.7%) 1.781 (1.506-2.106) <0.0001 1.989 (1.676-2.359) <0.0001 
Intermediate (ref.) 1 - 1 - 
High (>10.9%) 1.745 (1.476-2.063) <0.0001 1.602 (1.351-1.900) <0.0001 
CV death 
Low (≤7.7%) 1.870 (1.561-2.241) <0.0001 2.106 (1.751-2.532) <0.0001 
Intermediate (ref.) 1 - 1 - 
High (>10.9%) 1.683 (1.401-2.021) <0.0001 1.539 (1.276-1.855) <0.0001 
CV death/CV hosp. 
Low (≤7.7%) 2.144 (1.894-2.427) <0.0001 2.323 (2.048-2.634) <0.0001 
Intermediate (ref.) 1 - 1 - 
High (>10.9%) 1.541 (1.353-1.754) <0.0001 1.360 (1.192-1.552) <0.0001 
*model adjusted on age, sex, race, hypertension, diabetes, peripheral vascular disease, chronic obstructive pulmonary 
disease, left ventricular ejection fraction, hemoglobin, sodium, estimated glomerular filtration rate, systolic blood 
pressure, loop diuretics, ACEi/ARBs, beta-blockers, and eplerenone allocation.   
Figure 1. “Spline” graphical representation of the prognostic implications of blood pressure 
variability 
 
 
Legend: SBP, systolic blood pressure; CV, cardiovascular. 
Model adjusted on age, sex, race, hypertension, diabetes, peripheral vascular disease, chronic obstructive pulmonary 
disease, left ventricular ejection fraction, hemoglobin, sodium, estimated glomerular filtration rate, systolic blood 
pressure, loop diuretics, ACEi/ARBs, beta-blockers, and eplerenone allocation.   
 
